Cargando…

Golimumab for the treatment of ulcerative colitis

The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Löwenberg, Mark, de Boer, Nanne KH, Hoentjen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958527/ https://www.ncbi.nlm.nih.gov/pubmed/24648749 http://dx.doi.org/10.2147/CEG.S48741

Ejemplares similares

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction
por: Hoentjen, Frank, et al.
Publicado: (2011)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
por: Iborra, Marisa, et al.
Publicado: (2020)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis
por: Kinoshita, Naohiko, et al.
Publicado: (2022)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
por: Perrig, Kathrin, et al.
Publicado: (2022)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis
por: Simsek, Melek, et al.
Publicado: (2019)

Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial
por: Löwenberg, Mark, et al.
Publicado: (2023)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
por: Nakamura, Shiro, et al.
Publicado: (2022)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
por: Tawa, Hideki, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
por: Rutgeerts, P., et al.
Publicado: (2015)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report
por: Alhalabi, Marouf M., et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan
por: Tokita, Kazuhide, et al.
Publicado: (2022)

Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab
por: Magro, Fernando, et al.
Publicado: (2019)

Oral health and salivary function in ulcerative colitis patients
por: Goldinova, Ariana, et al.
Publicado: (2020)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study
por: Derks, Monica EW, et al.
Publicado: (2023)

Safety and clinical efficacy of golimumab in the treatment of arthritides
por: Simsek, Ismail, et al.
Publicado: (2010)

Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months
por: Teich, Niels, et al.
Publicado: (2021)

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year
por: Gibson, Peter R, et al.
Publicado: (2016)

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis
por: Paccou, Julien, et al.
Publicado: (2016)

Tacrolimus for the Treatment of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2015)

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study
por: Vermeire, Séverine, et al.
Publicado: (2018)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6t09vagjhpp355q3o908r0pkcb